Zoetis account plan
Advancing animal health care
At a glance
Zoetis makes medicines, vaccines and diagnostics for pets and livestock: $9,467 million 2025 revenue, about 14,500 employees.
Zoetis, headquartered in Parsippany, New Jersey and a former Pfizer business unit, discovers, makes and sells animal health medicines, vaccines, diagnostics and biodevices for dogs, cats, horses, cattle, swine, poultry, fish and sheep. Its products are mostly prescription products sold through veterinarians and distributors, marketed directly in approximately 45 countries and sold in more than 100. FY2025 revenue was $9,467 million (+2%) and net income attributable to Zoetis $2,673 million. It had about 14,500 employees at 31 December 2025 and is led by CEO Kristin C. Peck.
Business units
United States
54% of 2025 revenue ($5,097 million)Companion animal products (83% of the segment) such as Simparica Trio, Apoquel, Cytopoint and Librela, plus livestock products. Q3 2026 revenue was $1,246 million (-6%), with companion animal down 8% on softer demand, new dermatology competition and generics, while livestock grew 5%. Abhay Nayak leads U.S. Commercial Operations.
International
45% of 2025 revenue ($4,254 million)Companion animal (56%) and livestock (44%) products across markets led by Brazil, Australia, the United Kingdom and Canada, including the Pharmaq aquatic vaccines business. Q3 2026 revenue was $1,116 million (+4% reported), with livestock up 8% on cattle and fish vaccines in Norway.
Contract manufacturing and human health (Client Supply Services)
about 1% of 2025 revenue ($116 million)Contract manufacturing for third parties and in vitro diagnostic products for human health, reported with the veterinary R&D organisation under other business activities.
Strategic priorities
- Defending dermatology and parasiticide share
- Leverage portfolio diversity where share pressure is most acute, with Apoquel Chew conversion, gross-to-net promotions and bundling while protecting list price; U.S. derm share loss slowed to 4 points in Q3 2026 from about 7 in Q2.
- Expanding access to established franchises
- Medical affairs and the new Zoetis Medical Hub, Simparica Duo expected as a new Rx product, and Lenivia and Portela broadening OA pain options.
- Innovation pipeline
- A significant major market approval every year for several years, long-acting Cytopoint launching in the first half of next year, and new categories targeted: chronic kidney disease, oncology, cardiology, obesity, diabetes and anxiety.
- Cost and productivity program
- A comprehensive cost and productivity program focused on cost of goods and SG&A, with restructuring costs of $142 million over the first nine months of 2026.
- ERP transition
- A multi-year move to a new ERP system, starting with eliminating the one-month reporting lag for international subsidiaries from 1 January 2026.
Latest results
Q3 2026 revenue was $2,391 million against $2,422 million (-1% reported, -2% operational), as lower net price, lower key franchise volume and the MFA divestiture outweighed growth elsewhere. Net income attributable to Zoetis fell 18% to $591 million, while adjusted diluted EPS was $1.75 versus $1.70 on a lower share count. Key dermatology sales fell 16% globally to $396 million, while livestock rose 7% to $797 million and companion animal diagnostics 13%. Full-year 2026 guidance is revenue of $9.22 billion to $9.32 billion and adjusted diluted EPS of $6.25 to $6.35, with a sequential high-single-digit revenue decline expected in Q4.
Investments and deals
- Diagnostics acquisitions
- Veterinary Pathology Group (diagnostic laboratories in the U.K. and Ireland) in 2025 and VitalRADS, a veterinary teleradiology platform, in Q3 2026.
- Research and development
- R&D spending of $698 million in 2025 across more than 300 programs, with a pipeline the CEO says has 12 potential blockbusters.
- Capital expenditure
- Capex of $621 million in 2025 and $334 million in the first nine months of 2026, against $462 million a year earlier.
- Share buybacks
- 23.9 million shares repurchased for $3.2 billion in 2025, partly funded by $2.0 billion of convertible notes; $2.4 billion returned through buybacks and dividends in 2026 through Q3.
Challenges and risks
- New competition in dermatology
- New entrants use discounting, rebates and bundling to compete for existing patients; key dermatology sales fell 16% in Q3 2026.
- Fewer veterinary visits
- U.S. clinic visits are down 3% year-to-date across categories, as veterinary service costs have risen 50% since 2022.
- Generic competition
- Generics hit Convenia and Cerenia in the U.S., and Draxxin's U.S. sales have declined 66% since 2021.
- Price pressure
- Price realization for 2026 is expected at 0% to -1%, and Q3 2026 net price fell about 1%.
- Tariffs, FX and debt
- Tariffs may hurt demand and raise costs, about 45% of nine-month 2026 revenue was in foreign currencies, and the company carries about $9.2 billion of unsecured notes.
What leadership says
“Zoetis has built leading categories before. We know how to defend them, evolve them, and build what comes next.”
“taking costs out where needed to operate more efficiently while protecting investments in innovation”
“veterinary service costs have risen 50% since 2022”
Where a supplier can help
- Cost and productivity savings
- The comprehensive cost and productivity program targets cost of goods and SG&A; procurement, manufacturing efficiency and automation suppliers can tie their offer to it.
- ERP and finance transformation
- The multi-year ERP transition and the reporting alignment of international subsidiaries create work for ERP integrators, finance process and data migration partners.
- Commercial effectiveness and direct-to-consumer marketing
- Defending dermatology and parasiticide share relies on clinic promotions, bundling and point-of-sale direct-to-consumer advertising; marketing analytics and trade promotion tools fit that priority.
- Diagnostics growth
- With diagnostics described as a strategic enabler and VPG and VitalRADS acquired, laboratory, imaging and data platform suppliers can support integration and scale.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Zoetis?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Zoetis Inc. Annual Report on Form 10-K for fiscal year 2025
- Zoetis is the largest animal health company by revenue: medicines, vaccines, diagnostics, biodevices, genetic tests and precision animal health across eight core species, with approximately 300 product lines sold in more than 100 countries and direct marketing in approximately 45 countries.
- FY2025 revenue was $9,467 million (+2% reported, +3% operational); net income attributable to Zoetis $2,673 million (+8%); adjusted net income $2,847 million (+6%).
- Two geographic segments: U.S. $5,097 million (54% of revenue, 83% companion animal) and International $4,254 million (45%, 56% companion animal); contract manufacturing and human health about 1%.
- Companion animal products are approximately 70% of revenue ($6,587 million, +5%); livestock approximately 29% ($2,764 million, -5%, reflecting the medicated feed additive divestiture to Phibro).
- Concentration: Simparica/Simparica Trio (~16%) and Apoquel/Apoquel Chewable (~12%) lead; the top five product lines (with Cytopoint, Librela, ceftiofur) are ~42% of revenue; the largest customer, a U.S. veterinary distributor, ~16%.
- About 14,500 employees (about 6,800 in the U.S.), a sales organization of about 3,900, 1,700 in R&D; R&D spend $698 million; 21 owned manufacturing sites and over 90 CMOs.
- Strategy: lead through innovation (new mAbs Lenivia and Portela approved in EU and Canada in 2025), customer experience, digital and data, colleagues, sustainability, and performing with agility.
- Capital: 23.9 million shares repurchased for $3.2 billion in 2025, partly funded by a $2.0 billion 0.250% convertible note; about $9.2 billion of unsecured debt; $2.4 billion left on the $6 billion buyback authorization.
- Key risks: dependence on top-selling products, generic competition (Draxxin U.S. sales down 66% since 2021; Cerenia, Excede), new competitors, changing distribution channels, disease outbreaks, tariffs and FX (approximately 42% of revenue in foreign currencies).
- In 2026 Zoetis eliminates the one-month reporting lag of international subsidiaries; this pulled an estimated 2.5% to 3.5% of extra International sales into reported Q4 2025.
- Zoetis Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 revenue was $2,391 million, down 1% (down 2% operational). The cause was a 1% volume decrease in key franchises, a 1% lower net price realization and a 1% MFA divestiture effect, partly offset by other in-line products.
- Nine-month revenue was $7,121 million, flat (down 1% operational). Net income was $1,883 million (-8%) and adjusted net income $2,147 million (-1%).
- U.S. segment Q3 revenue was $1,246 million (-6%): companion animal $980 million (-8%) and livestock $266 million (+5%). U.S. earnings fell 8% to $830 million.
- Companion animal drivers: softer end-market demand, heightened competition in the key dermatology franchise, macro-driven price sensitivity, and generics on Convenia and Cerenia.
- International Q3 revenue was $1,116 million (+4%, +3% operational). Companion animal was flat operationally (parasiticides and the new long-acting mAbs Lenivia and Portela offset lower dermatology); livestock grew on cattle and fish.
- Q3 net income was $591 million (-18%), hit by impairment of PetMedix in-process R&D assets. Restructuring of $142 million over nine months came under a "comprehensive cost and productivity program".
- Since 1 January 2026 international subsidiaries report without the one-month lag; prior periods have been recast.
- VitalRADS (veterinary teleradiology) was acquired in Q3. $770 million remained under the $6 billion buyback authorization at 30 September 2026.
- Zoetis Q3 2026 earnings call (corrected transcript)
- CEO Kristin Peck: Q3 revenue and adjusted net income declined "in line with our expectations". Full-year revenue guidance was narrowed to the high end of the range: $9.22 billion to $9.32 billion (-2% to -1% organic operational). Adjusted EPS guidance was raised to $6.25 to $6.35.
- Market backdrop: veterinary service costs have risen 50% since 2022, fewer dogs are joining households as cat ownership grows, and U.S. clinic visits are down 3% year-to-date.
- Three priorities: leverage portfolio diversity, expand access to established franchises, and advance innovation while taking costs out.
- Key dermatology fell 16% globally to $396 million. Gross-to-net promotions slowed U.S. derm share loss to 4 points in Q3 from about 7 points in Q2; the goal is to get it to zero.
- Simparica franchise +1% ($358 million). Simparica Trio held a 22.5% U.S. share; Simparica Duo approval is expected by year end.
- OA pain mAbs $137 million (+2%): International +13% on Lenivia and Portela, U.S. -12% on Librela.
- Livestock grew 7% to $797 million and companion animal diagnostics 13% to $122 million (VitalRADS, VPG). Long-acting Cytopoint U.S. approval is expected in Q4, with launch in the first half of next year.
- New CFO and COO Jay Saccaro: 2027 will be planned prudently, assuming no improvement in the macro or competitive situation. The pipeline matters more for 2028-2029. Costs (COGS and SG&A) are the focus.
- Zoetis Q2 2026 earnings call (corrected transcript)
- Q2 2026 fell short of expectations: revenue $2.5 billion, flat reported and -1% organic operational. U.S. revenue -7%, International +6%, livestock +11%, companion animal -6%.
- Guidance was cut to $9.12 billion to $9.32 billion revenue (-3% to -1% organic operational), adjusted net income $2.57 billion to $2.62 billion, and adjusted EPS $6.15 to $6.25.
- Peck: new entrants are using "higher levels of discounting, rebates, cross-portfolio, bundling" to compete for existing patients, not expanding the market. Clinic visits keep falling as vet prices outpace inflation.
- Response: targeted gross-to-net investments (promotions, rebates, point-of-sale offers) rather than list price cuts, cost discipline (adjusted SG&A -4%), and continued R&D. The pipeline has "12 potential blockbusters".
- Leadership: Abhay Nayak was promoted to EVP and President, U.S. Commercial Operations. Jay Saccaro (ex-CFO of GE HealthCare and Baxter) joins as CFO and COO in a newly created role on 17 August; Wetteny Joseph stays as special advisor until early 2027.
- U.S. key dermatology fell 18% to $251 million; U.S. derm in-clinic share was about 86%, down 5 points sequentially. Simparica Trio U.S. in-clinic share was about 21%.
- Bright spots: U.S. livestock +23% (New World screwworm demand, supply), International Simparica +19%, companion animal diagnostics +12%, and VitalRADS teleradiology acquired.
Questions about Zoetis
What does Zoetis do?
Zoetis develops, makes and sells medicines, vaccines, diagnostics and biodevices for companion animals and livestock, mostly sold through veterinarians.
What is Zoetis's revenue?
FY2025 revenue was $9,467 million, up 2%. For 2026 Zoetis guides revenue of $9.22 billion to $9.32 billion.
How many employees does Zoetis have?
About 14,500 employees at 31 December 2025, about 6,800 in the U.S. and 7,700 elsewhere.
Who leads Zoetis?
Kristin C. Peck is CEO, and Jay Saccaro joined as EVP, Chief Financial Officer and Chief Operating Officer in 2026.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)